However, our findings unveil a new pro-oncogenic axis, involving TAZ-AS202, E2F1 and EPH-Ephrin signaling, which supports NSCLC tumorigenesis and which can be exploited for future therapeutic targeting. This evidence concerns the gene EPHA1 and non-small cell lung carcinoma.